UK-453,061 (lersivirine), a Pfizer drug now being developed by ViiV Healthcare, is a second-generation NNRTI. It does not seem to have a significant effect on CYP3A4 metabolic activity and  appears to be active against the common NNRTI mutations. It is enrolling patients into a phase II study comparing UK-453,061 to efavirenz, both taken with Truvada.1


  1. Fatkenheuer G et al. Short-term monotherapy with UK-453,061, a novel NNRTI, reduces viral load in HIV-infected patients. Fourth International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, Sydney, abstract WESS202, 2007